Ekso Bionics (NASDAQ:EKSO) Now Covered by Analysts at Lake Street Capital

Lake Street Capital began coverage on shares of Ekso Bionics (NASDAQ:EKSOFree Report) in a research note issued to investors on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $2.50 price target on the stock.

A number of other analysts have also weighed in on the company. StockNews.com started coverage on Ekso Bionics in a research report on Thursday, June 20th. They set a hold rating on the stock. HC Wainwright upped their price objective on Ekso Bionics from $9.25 to $10.00 and gave the stock a buy rating in a research report on Tuesday, April 30th.

Check Out Our Latest Report on EKSO

Ekso Bionics Stock Up 2.9 %

Shares of NASDAQ EKSO opened at $1.05 on Monday. Ekso Bionics has a 52-week low of $0.62 and a 52-week high of $3.13. The business’s 50 day moving average is $1.21 and its two-hundred day moving average is $1.60. The company has a quick ratio of 2.11, a current ratio of 2.81 and a debt-to-equity ratio of 0.33. The firm has a market cap of $19.08 million, a price-to-earnings ratio of -1.08 and a beta of 1.49.

Ekso Bionics (NASDAQ:EKSOGet Free Report) last posted its quarterly earnings data on Monday, April 29th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). Ekso Bionics had a negative return on equity of 95.36% and a negative net margin of 79.48%. The company had revenue of $3.76 million for the quarter, compared to analysts’ expectations of $4.99 million. During the same period in the prior year, the company posted ($0.33) EPS. Research analysts predict that Ekso Bionics will post -0.43 EPS for the current year.

Hedge Funds Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Strategic Wealth Investment Group LLC increased its position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSOFree Report) by 21.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,950 shares of the company’s stock after purchasing an additional 9,285 shares during the period. Strategic Wealth Investment Group LLC owned 0.37% of Ekso Bionics worth $130,000 at the end of the most recent quarter. 6.42% of the stock is currently owned by institutional investors.

About Ekso Bionics

(Get Free Report)

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.

Further Reading

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.